Abstract:Background Pulmonary hypertension (PH) is a deadly disease characterized by vascular stiffness and altered cellular metabolism. Current treatments focus on vasodilation and not other root causes of pathogenesis. Previously, it was demonstrated that glutamine metabolism, as catalyzed by GLS1 (glutaminase 1) activity, is mechanoactivated by matrix stiffening and the transcriptional coactivators YAP1 (yes‐associated protein 1) and transcriptional coactivator with PDZ‐binding motif (TAZ), resulting in pulmonary vascular proliferation and PH. Pharmacologic inhibition of YAP1 (by verteporfin) or glutaminase (by CB‐839) improved PH in vivo. However, systemic delivery of these agents, particularly YAP1 inhibitors, may have adverse chronic effects. Furthermore, simultaneous use of pharmacologic blockers may offer additive or synergistic benefits. Therefore, a strategy that delivers these drugs in combination to local lung tissue, thus avoiding systemic toxicity and driving more robust improvement, was investigated. Methods and Results We used poly(lactic‐co‐glycolic) acid polymer‐based microparticles for delivery of verteporfin and CB‐839 simultaneously to the lungs of rats suffering from monocrotaline‐induced PH. Microparticles released these drugs in a sustained fashion and delivered their payload in the lungs for 7 days. When given orotracheally to the rats weekly for 3 weeks, microparticles carrying this drug combination improved hemodynamic (right ventricular systolic pressure and right ventricle/left ventricle+septum mass ratio), histologic (vascular remodeling), and molecular markers (vascular proliferation and stiffening) of PH. Importantly, only the combination of drug delivery, but neither verteporfin nor CB‐839 alone, displayed significant improvement across all indexes of PH. Conclusions Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 and GLS1 improved PH in rats, addressing unmet needs for the treatment of this deadly disease. Nonstandard Abbreviations and Acronyms GLS1 glutaminase 1 PH pulmonary hypertension PLGA poly(lactic‐co‐glycolic) acid RVSP right ventricular systolic pressure TAZ transcriptional coactivator with PDZ‐binding motif YAP1 yes‐associated protein 1 Clinical Perspective What Is New? Simultaneous, lung‐specific, and controlled release of drugs targeting YAP1 (yes‐associated protein 1) and GLS1 (glutaminase 1) and encapsulated by poly(lactic‐co‐glycolic) acid polymer‐based microparticles act together to improve pulmonary hypertension in rats. Such targeted combinatorial therapy performs better across multiple indexes of disease than delivery of a poly(lactic‐co‐glycolic) acid polymer‐based single drug and at much lower doses than used for systemic administration. What Are the Clinical Implications? These results carry broad implications regarding the development of specific, next‐generation drug combinations for pulmonary vascular disease and perhaps for pulmonary conditions beyond pulmonary hypertension that affect both normal health and disease. Pulmonary hypertension (PH) is a poorly understood vascular disease with increasing prevalence worldwide but with inadequate treatment options. 1 There exist more than a dozen approved vasodilator drugs for treatment of this disease; nonetheless, mortality rates with current therapies remain high. At the cellular and molecular levels in the diseased pulmonary vasculature, PH is characterized by metabolic dysregulation, pro‐proliferative states, and adverse pulmonary vascular remodeling and stiffness. As such, there have been recent efforts to develop novel pharmacologic approaches that target the molecular origins of PH and thus could represent disease‐modifying opportunities. Recently, we reported a key molecular connection between vessel stiffness and metabolic dysregulation that promotes PH. Namely, we found that vessel stiffness mechanoactivates the YAP1 (yes‐associated protein 1)/TAZ (transcriptional coactivato -Abstract Truncated-

Inhibition of Glucose-6-Phosphate Dehydrogenase Activity Attenuates Right Ventricle Pressure and Hypertrophy Elicited by VEGFR Inhibitor + Hypoxia

Capping Protein Gelsolin-Like As A Therapeutic Target to Prevent Hypoxic Pulmonary Hypertension

Hypoxic Activation of G6PD Controls the Expression of Genes Involved in the Pathogenesis of Pulmonary Hypertension Through the Regulation of DNA Methylation.

Loss of M6a Demethylase ALKBH5 Alleviates Hypoxia-Induced Pulmonary Arterial Hypertension Via Inhibiting Cyp1a1 Mrna Decay

Inhibition of Anaplerosis Attenuated Vascular Proliferation in Pulmonary Arterial Hypertension

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease

Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway

PGC-1α-mediated angiogenesis prevents pulmonary hypertension in mice

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Mutual Promotion of FGF21 and PPARγ Attenuates Hypoxia-Induced Pulmonary Hypertension

Abstract 306: Endothelial 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase, Isoform 3 (PFKFB3) Deficiency Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice

Abstract 11289: Suppression of <i>De Novo</i> Purine Synthesis Reduces Development and Progression of Pulmonary Hypertension in Rodent Models

Simultaneous Pharmacologic Inhibition of Yes-Associated Protein 1 and Glutaminase 1 via Inhaled Poly(Lactic-co-Glycolic) Acid-Encapsulated Microparticles Improves Pulmonary Hypertension.

The role of 6-phosphogluconate dehydrogenase in vascular smooth muscle cell phenotypic switching and angioplasty-induced intimal hyperplasia

Selective Targeting HIF‐2α for Treatment of Pulmonary Arterial Hypertension

PFKFB3-mediated Endothelial Glycolysis Promotes Pulmonary Hypertension.

Endothelial 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase, Isoform 3 (PFKFB3) Deficiency Inhibits Hypoxia-Induced Pulmonary Hypertension in Mice

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Reversal of Pulmonary Hypertension in a Human-Like Model: Therapeutic Targeting of Endothelial DHFR

Enhanced lung endothelial glycolysis is implicated in the development of severe pulmonary hypertension in type 2 diabetes

Selective inhibition of Histone deacetylases reverses vascular remodeling and improves right ventricle function in pulmonary hypertension